Panevezio Statybos Lt 1 Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Panevezio Statybos Lt 1 in den nächsten Jahren?
Pro
?
L*********** I********** f** d** n******* J****
?
U****************
?
A****************
Kontra
?
M************
?
M****
?
W******* i* V********
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Panevezio Statybos Lt 1 im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Panevezio Statybos Lt 1 | - | - | - | - | - | - | - |
| J+p-Avax S.a. Nam. Eo 0,58 | 0,00 % | 11,09 % | -3,96 % | 50,24 % | 44,06 % | 151,59 % | 280,58 % |
| Verbrec Ltd. | -7,02 % | -13,11 % | -3,64 % | 135,56 % | -7,02 % | 107,84 % | 24,71 % |
| Inypsa | 0,85 % | 3,63 % | -6,76 % | -17,63 % | -1,55 % | -21,61 % | -9,12 % |
News
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Key Points
- Interested in Bicara Therapeutics Inc.? Here are five stocks we like better.
- Bicara Therapeutics said new ASCO data support ficerafusp alfa in first-line recurrent or metastatic
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA